NCT00856336View on ClinicalTrials.gov

Phase I Safety Study of DMXAA in Refractory Tumors

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

May 31, 2003

Primary Completion Date

January 31, 2004

Study Completion Date

January 31, 2004

Conditions

Refractory Tumors

Interventions

DRUG

DMXAA

DMXAA, given intravenously over 20 minutes. Patients were to each undergo six doses of treatment at weekly intervals, receiving each of six doses (300, 600, 1200, 1800, 2400 and 3000 mg/m2)